银杏酮酯分散片联合常规疗法治疗缺血性脑卒中临床观察

Clinical Observation of Ginkgo Biloba Extract Dispersible Tablets Combined with Conventional Therapy for Ischemic Stroke

目的 :观察在常规治疗基础上加用银杏酮酯分散片治疗缺血性脑卒中患者的效果。方法 :选取本院收治的80例血瘀型缺血性脑卒中患者作为研究对象,随机分为观察组与对照组各40例,2组患者入院后均给予常规治疗,观察组在此基础上给予银杏酮酯分散片治疗,对照组给予阿司匹林肠溶片治疗,以1周为1疗程,连续治疗2疗程。观察比较2组的临床疗效;治疗前后对2组患者的血液流变学指标(全血黏度、血浆黏度、纤维蛋白原、红细胞压积)进行测定,评价美国国立卫生院神经功能缺损评分(NIHSS)、简易精神状态评价量表(MMSE)评分;随访6月,对2组患者的病情复发情况进行统计。结果:观察组总有效率90.0%,优于对照组的67.5%,2组比较,差异有统计学意义(P<0.05)。2组全血黏度、血浆黏度、纤维蛋白原、红细胞压积较治疗前均下降(P<0.05),观察组各项指标值均低于对照组(P<0.05)。2组NIHSS、MMSE评分较治疗前均有改善(P<0.05),观察组NIHSS低于对照组,MMSE评分高于对照组,差异均有统计学意义(P<0.05)。观察组复发率为0,对照组复发率为26.7%,2组复发率比较,差异有统计学意义(P<0.05)。结论:在常规治疗基础上加用银杏酮酯分散片治疗血瘀型缺血性脑卒中患者临床疗效显著,可有效改善患者的血液流变学指标、神经功能缺损程度和认知功能障碍,对脑卒中可起到二级预防作用。

Objective; To observe the effect of ginkgo biloba extract dispersible tablets combined with conventional therapy for ischemic stroke. Methods.. Selected 80 cases of patients with ischemic stroke of blood stasis type in our hospital as study objects, and divided them into the observation group and the control group randomly, 40 cases in each group. Both groups received conventional therapy after hospitalization. Moreover, the observation group was treated with ginkgo biloba extract dispersible tablets, and the control group was treated with aspirin enteric-coated tablets. Both groups received treatment for one week as a course, two courses in total. Compared the clinical effect and determined hemorheology indexes （whole blood viscosity, plasma viscosity, fibrinogen and hematocrit） in both groups before and after treatment. Evaluated national institute of health stroke scale （NIHSS） and minimum mental state examination （MMSE） in both groups. Recorded recurrence in both groups during six-months of follow-up. Results： The total effective rate was 90.0% in the observation group, being superior to 67.5% in the control group（P〈 0.05）. Whole blood viscosity, plasma viscosity, fibrinogen, hematocrit in both groups were decreased when compared with those before treatment （P 〈 0.05）, and all indexes in the observation group were lower than those in the control group （P〈 0.05）. Scores of NIHSS and MMSE were improved, comparing with those before treatment （P〈 0.05）. NIHSS scores in the observation group were lower than those in the control group, while MMSE scores in the observation group were higher than those in the control group（P 〈 0.05）. The recurrence rate was 0 in the observation group and 26.7% in the control group, the difference being significant （P〈 0.05）. Conclusion： The therapy of ginkgo biloba extract dispersible tablets based on conventional therapy for patients with ischemic stroke of blood stasis type has evident curative effect. It can effectively improve hemorheology indexes, harmful degree of nervous function and cognitive impairment. It also has secondary prevention effect on stroke.